ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
FDA sets new date for panel review of Sarepta's muscle drug
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 34489" data-attributes="member: 3"><p>An independent panel of experts to the U.S. Food and Drug Administration (FDA) will discuss Sarepta Therapeutics Inc's muscle wasting drug on April 25, nearly three months after the original date.</p><p>The agency on Jan. 20 postponed the meeting evaluating the company's keenly watched Duchenne muscular dystrophy drug, eteplirsen, due to an inclement weather forecast for Washington DC. (<a href="http://1.usa.gov/24T8HOa" target="_blank">1.usa.gov/24T8HOa</a>)</p><p>FDA staff on Jan. 15 had said they were unconvinced about eteplirsen's efficacy and trial design, a day after the regulator rejected Kyndrisa, a rival drug developed by BioMarin Pharmaceutical Inc.</p><p>Eteplirsen, like Kyndrisa, is designed to treat a subset of patients with DMD, which hampers muscle movement and affects one in 3,600 newborn boys, with most patients dying by the age of 30.</p><p></p><p><a href="http://mobile.reuters.com/article/idUSKCN0WC2FG" target="_blank">http://mobile.reuters.com/article/idUSKCN0WC2FG</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 34489, member: 3"] An independent panel of experts to the U.S. Food and Drug Administration (FDA) will discuss Sarepta Therapeutics Inc's muscle wasting drug on April 25, nearly three months after the original date. The agency on Jan. 20 postponed the meeting evaluating the company's keenly watched Duchenne muscular dystrophy drug, eteplirsen, due to an inclement weather forecast for Washington DC. ([URL="http://1.usa.gov/24T8HOa"]1.usa.gov/24T8HOa[/URL]) FDA staff on Jan. 15 had said they were unconvinced about eteplirsen's efficacy and trial design, a day after the regulator rejected Kyndrisa, a rival drug developed by BioMarin Pharmaceutical Inc. Eteplirsen, like Kyndrisa, is designed to treat a subset of patients with DMD, which hampers muscle movement and affects one in 3,600 newborn boys, with most patients dying by the age of 30. [url]http://mobile.reuters.com/article/idUSKCN0WC2FG[/url] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
FDA sets new date for panel review of Sarepta's muscle drug
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top